Arterial Blood Pressure Pharmacological Treatment in Latvia: from Patients´ Perspective Applying the EQ-5D-5L Questionnaire

Description

Cardiovascular diseases are a leading cause of death globally. Non-adherence to medical arterial hypertension (AH) treatment remains low (45.9%). The number of comparative studies of patient related outcomes in the treatment of AH is limited. Aim of the study was to evaluate the generic quality of life in patients with AH treated pharmacologically by using EQ-5D-5L questionnaire.. Interviewer-administered, face-to-face cross-sectional survey/multicentre study (outpatient hospitals) was performed from 5 December 2022 to 15 December 2022. Respondents rated their level of impairment across dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), global health rating on a visual analogue scale (EQ-VAS). The study group comprised 244 patients with AH treated pharmacologically, stratified by the use of fixed-dose or multiple pill regimen.. Fixed-dose combinations (FDC) received 66.4% (n=162) patients, from them controlled AH reported 67.9% (n=110) of patients and in multiple-pill dose regimen (n=82) controlled AH was observed in 39.0% (n=32). Patients reported most significant data on anxiety/depression – being extremely anxious in uncontrolled AH and multiple-pill regimen, severely anxious in multiple-pill dose, moderately and slightly anxious in all treatment groups and both – controlled and uncontrolled AH. Slightly reduced self-care, usual activities, mobility, discomfort observed mostly in multiple-pill regimen in both groups. Reporting full health in FDC group with controlled AH – 74.5%, uncontrolled AH – 67.3% while in multiple-pill dose treatment and controlled AH – 56.2%, uncontrolled AH – 34.0%.. Change from multiple-pill dose regimen to FDC improves generic quality of life in patients with AH treated pharmacologically. Although a five-level version of the widely used EuroQol 5 dimensions (EQ-5D-5L) instrument has been developed, population norms are not yet available for Latvia to inform the future valuation of health in economic evaluations. Future studies should be aimed to estimate health-related quality of life normative values for the EQ-5D-5L preference-based measure in Latvia.

Period	29 Mar 2023
Event title	RSU Research week 2023: Society. Health. Welfare
Event type	Conference
Conference number	9
Organiser	Rīga Stradiņš University
Location	Riga, LatviaShow on map
Degree of Recognition	International